Adélia Maria de Miranda Henriques-Souza

Adélia Maria de Miranda Henriques-Souza

Auto-generated profile, based on publicly available information

Adélia Maria de Miranda Henriques-Souza

Instituto de Medicina Integral Professor Fernando Figueira, Recife PE, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2017 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
MFMaria Lucia Brito Ferreira
Maria Lucia Brito Ferreira
CBCARLOS ANTUNES BRITO
CARLOS ANTUNES BRITO
ÁMÁlvaro José Porto Moreira
Álvaro José Porto Moreira
MMMaria Íris de Morais Machado
Maria Íris de Morais Machado
AHAdélia Henriques-Souza
Adélia Henriques-Souza
LPLindomar José Pena
Lindomar José Pena
Zika virus (ZIKV) emerged in Brazil in 2015, which was followed by an increase of Guillain–Barre Syndrome (GBS) cases. We report the epidemiological, clinical, and laboratory findings of the first six neurological cases associated with ZIKV in Brazil seen in a reference neurology hospital in Pernambuco, Brazil. In all cases, ZIKV was detected in serum and/or cerebrospinal fluid (CSF) samples. In this case series, four cases were defined as GBS, one as acute disseminated encephalomyelitis (ADEM) and the other as encephalitis. ZIKV was detected in all cases by RT-PCR and virus isolation was successful in two patients. The time between ZIKV acute symptoms and the development of neurological manifestations varied from 3 to 13 days and ZIKV was detected between 15 and 34 days after the initial symptoms. Our results highlight the need to include ZIKV as a differential diagnosis for neurological syndromes in countries with circulation of this arbovirus. Because the viremia in these patients appears to persist longer, direct diagnostic techniques such as RT-PCR and viral isolation should be considered even if it is after the acute phase of viral infection.

1 October 2020 in Neuroradiology
Verified
Journal Article
Open access
PDF file
AHAdélia Maria de Miranda Henriques-Souza
Adélia Maria de Miranda Henriques-Souza
AMAna Cláudia Marques Gouveia de Melo
Ana Cláudia Marques Gouveia de Melo
BMBianca de Aguiar Coelho Silva Madeiro
Bianca de Aguiar Coelho Silva Madeiro
LFLeonardo Furtado Freitas
Leonardo Furtado Freitas
PRPedro Augusto Sampaio Rocha-Filho
Pedro Augusto Sampaio Rocha-Filho
FGFabrício Goncalves
Fabrício Goncalves
The authors present a case of acute disseminated encephalomyelitis in a COVID-19 pediatric patient with positive SARS-CoV2 markers from a nasopharyngeal swab. A previously healthy 12-year-old-girl presented with a skin rash, headache, and fever. Five days after that, she had an acute, progressive, bilateral, and symmetrical motor weakness. She evolved to respiratory failure. Magnetic resonance imaging (MRI) of the brain and cervical spine showed extensive bilateral and symmetric restricted diffusion involving the subcortical and deep white matter, a focal hyperintense T2/FLAIR lesion in the splenium of the corpus callosum with restricted diffusion, and extensive cervical myelopathy involving both white and gray matter. Follow-up examinations of the brain and spine were performed 30 days after the first MRI examination. The images of the brain demonstrated mild dilatation of the lateral ventricles and widespread widening of the cerebral sulci, complete resolution of the extensive white matter restricted diffusion, and complete resolution of the restricted diffusion in the lesion of the splenium of the corpus callosum, leaving behind a small gliotic focus. The follow-up examination of the spine demonstrated nearly complete resolution of the extensive signal changes in the spinal cord, leaving behind scattered signal changes in keeping with gliosis. She evolved with partial clinical and neurological improvement and was subsequently discharged.

10 August 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
CBCarlos A. A. Brito
Carlos A. A. Brito
AHAdélia Henriques-Souza
Adélia Henriques-Souza
CSCynthia Soares
Cynthia Soares
PCPriscila Mayrelle Da Silva Castanha
Priscila Mayrelle Da Silva Castanha
LMLaís C. Machado
Laís C. Machado
Rafael FrançaRafael França
Rafael França
Zika virus (ZIKV) is a recently emerged arbovirus, which infection during pregnancy is associated with a series of congenital malformations, collectively denominated Congenital Zika Syndrome (CZS). Following infection, ZIKV RNA has a median duration period of 10 days in plasma and up to 6 months in semen in immunocompetent adult individuals. Moreover, ZIKV is able to replicate and persist in fetal brains and placentas, consequently, infection is associated with pregnancy loss, albeit the pathogenic mechanisms are still unknown. Here we report a CZS case of an infant born during the ZIKV outbreak in northeast Brazil, the child presented recurrent episodes of seizures with prolonged presence of ZIKV RNA on the central nervous system (CNS) and blood. ZIKV RNA was identified and partially sequenced from a sample of cerebrospinal fluid (CSF) obtained from the infant with 6 months of life, and later from another sample after the infant completed 17 months of life. Commonly congenital infections were discarded based on STORCH (syphilis, toxoplasmosis, rubella, cytomegalovirus and herpes simplex virus) negative laboratory results. Presence of specific ZIKV antibodies on both mother and children confirmed the association of severe microcephaly and ZIKV infection, diagnosed after birth. Altogether, our data raise the possibility that CZS cases may result in prolonged viral presence, these findings could be useful for therapy and diagnostic recommendations.

1 March 2023 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
LSLetícia Sampaio
Letícia Sampaio
MMMaria Luiza Giraldes de Manreza
Maria Luiza Giraldes de Manreza
APAndré Luiz Santos Pessoa
André Luiz Santos Pessoa
JGJuliana Gurgel-Giannetti
Juliana Gurgel-Giannetti
ACAna Carolina Coan
Ana Carolina Coan
FKFernando Kok
Fernando Kok
Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare neurodegenerative genetic disease that affects children in early life. Its classic form is rapidly progressive, leading to death within the first 10 years. The urge for earlier diagnosis increases with the availability of enzyme replacement therapy. A panel of nine Brazilian child neurologists combined their expertise in CLN2 with evidence from the medical literature to establish a consensus to manage this disease in Brazil. They voted 92 questions including diagnosis, clinical manifestations, and treatment of the disease, considering the access to healthcare in this country. Clinicians should suspect CLN2 disease in any child, from 2 to 4 years old, with language delay and epilepsy. Even though the classic form is the most prevalent, atypical cases with different phenotypes can be found. Electroencephalogram, magnetic resonance imaging, molecular and biochemical testing are the main tools to investigate and confirm the diagnosis. However, we have limited access to molecular testing in Brazil, and rely on the support from the pharmaceutical industry. The management of CLN2 should involve a multidisciplinary team and focus on the quality of life of patients and on family support. Enzyme replacement therapy with Cerliponase α is an innovative treatment approved in Brazil since 2018; it delays functional decline and provides quality of life. Given the difficulties for the diagnosis and treatment of rare diseases in our public health system, the early diagnosis of CLN2 needs improvement as enzyme replacement therapy is available and modifies the prognosis of patients.

1 April 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
MMMaria Luiza Giraldes de Manreza
Maria Luiza Giraldes de Manreza
TPTatiane Amaral Pan
Tatiane Amaral Pan
ECEduardo Quinalha Carbone
Eduardo Quinalha Carbone
AVAntonio Carlos Amedeo Vattimo
Antonio Carlos Amedeo Vattimo
RHRenata Herrera
Renata Herrera
EYElza Márcia Targas Yacubian
Elza Márcia Targas Yacubian
Background: Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality. Objective: The aim of treatment with antiseizure medications (ASMs) is to allow patients to remain without seizures, with good tolerability. Levetiracetam is a broad-spectrum ASM with a unique mechanism of action that differs it from other ASMs. It has been shown to be effective and safe for treating adults and children with epilepsy. Methods: This was a phase III, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of levetiracetam in children and adults (4-65 years) as an adjuvant treatment for focal-onset seizures. It was conducted among 114 patients undergoing treatment with up to three ASMs. The primary efficacy analysis was based on the proportion of patients who achieved a reduction of ≥ 50% in the mean number of focal seizures per week, over a 16-week treatment period. The patients were randomized to receive placebo or levetiracetam, titrated every two weeks from 20 mg/kg/day or 1,000 mg/day up to 60 mg/kg/day or 3,000 mg/day. Results: Levetiracetam was significantly superior to placebo (p = 0.0031); 38.7% of the participants in the levetiracetam group and 14.3% in the control group shows reductions in focal seizures. Levetiracetam was seen to have a favorable safety profile and an adverse event rate similar to that of placebo. Conclusion: Corroborating the results in the literature, levetiracetam was shown to be effective and safe for children and adults with refractory focal-onset epilepsy.

1 September 2023 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
LSLetícia Sampaio
Letícia Sampaio
AHAdélia Maria de Miranda Henriques-Souza
Adélia Maria de Miranda Henriques-Souza
MSMariana Ribeiro Marcondes da Silveira
Mariana Ribeiro Marcondes da Silveira
LSLisiane Seguti
Lisiane Seguti
MSMara Lúcia Schmitz Ferreira Santos
Mara Lúcia Schmitz Ferreira Santos
MMMaria Luíza Giraldes de Manreza
Maria Luíza Giraldes de Manreza
Background Infantile epileptic spasms syndrome (IESS) is a rare but severe condition affecting children early and is usually secondary to an identifiable brain disorder. It is related to psychomotor deterioration in childhood and epilepsy in adult life. Treatment is challenging as infantile spasms may not respond to most antiseizure medication, and relapse is frequent. Objective To evaluate the literature regarding treatment of IESS and provide a practical guidance to a healthcare system with limited resources. Methods An expert committee from the Brazilian Society of Child Neurology reviewed and discussed relevant scientific evidence in the treatment of IESS regarding the drugs available in Brazil. Results Oral prednisolone and vigabatrin are the most common drugs used as first-line therapy; they are efficient and affordable therapy as both are available in the Brazilian unified health system (SUS, in the Portuguese acronym). Intramuscular adrenocorticotropic hormone (ACTH) presents similar efficacy as oral prednisolone but has a higher cost and is not available in Brazil. Other antiseizure medications such as topiramate, levetiracetam, or benzodiazepines have limited response and are prescribed as adjuvant therapy. If the health service has nutritionists, a ketogenic diet should be implemented for those not responding to hormonal and vigabatrin treatment. Epilepsy surgery is mainly indicated for patients with focal lesions that do not respond to pharmacological therapy. Conclusion Early treatment of IESS with efficient drugs is feasible in our country. Using standard protocols increases the odds of achieving complete cessation in a shorter time and decreases relapse.